Skip to main content
NCBI home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1997 Feb 1;25(3):480–491. doi: 10.1093/nar/25.3.480

Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.

J G Moggs 1, D E Szymkowski 1, M Yamada 1, P Karran 1, R D Wood 1
PMCID: PMC146461  PMID: 9016585

Abstract

In order to understand the action of the chemotherapeutic drug cisplatin, it is necessary to determine why some types of cisplatin-DNA intrastrand crosslinks are repaired better than others. Using cell extracts and circular duplex DNA, we compared nucleotide excision repair of uniquely placed 1,2-GG, 1,2-AG, and 1,3-GTG cisplatin-crosslinks, and a 2-acetylaminofluorene lesion. The 1,3 crosslink and the acetylaminofluorene lesion were repaired by normal cell extracts approximately 15-20 fold better than the 1,2 crosslinks. No evidence was found for selective shielding of 1,2 cisplatin crosslinks from repair by cellular proteins. Fractionation of cell extracts to remove putative shielding proteins did not improve repair of the 1,2-GG crosslink, and cell extracts did not selectively inhibit access of UvrABC incision nuclease to 1,2-GG crosslinks. The poorer repair of 1,2 crosslinks in comparison to the 1,3 crosslink is more likely a consequence of different structural alterations of the DNA helix. In support of this, a 1,2-GG-cisplatin crosslink was much better repaired when it was opposite one or two non-complementary thymines. Extracts from cells defective in the hMutSalpha mismatch binding activity also showed preferential repair of the 1,3 crosslink over the 1,2 crosslink, and increased repair of the 1,2 adduct when opposite thymines, showing that hMutSalphais not involved in the differential NER of these substrates in vitro. Mismatched cisplatin adducts could arise by translesion DNA synthesis, and improved repair of such adducts could promote cisplatin-induced mutagenesis in some cases.

Full Text

The Full Text of this article is available as a PDF (450.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboussekhra A., Biggerstaff M., Shivji M. K., Vilpo J. A., Moncollin V., Podust V. N., Protić M., Hübscher U., Egly J. M., Wood R. D. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell. 1995 Mar 24;80(6):859–868. doi: 10.1016/0092-8674(95)90289-9. [DOI] [PubMed] [Google Scholar]
  2. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R. D., Boland C. R., Koi M., Fishel R. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996 Jul 1;56(13):3087–3090. [PubMed] [Google Scholar]
  3. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  4. Bedford P., Fichtinger-Schepman A. M., Shellard S. A., Walker M. C., Masters J. R., Hill B. T. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res. 1988 Jun 1;48(11):3019–3024. [PubMed] [Google Scholar]
  5. Bellon S. F., Coleman J. H., Lippard S. J. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 1991 Aug 13;30(32):8026–8035. doi: 10.1021/bi00246a021. [DOI] [PubMed] [Google Scholar]
  6. Billings P. C., Engelsberg B. N., Hughes E. N. Proteins binding to cisplatin-damaged DNA in human cell lines. Cancer Invest. 1994;12(6):597–604. doi: 10.3109/07357909409023044. [DOI] [PubMed] [Google Scholar]
  7. Bruhn S. L., Pil P. M., Essigmann J. M., Housman D. E., Lippard S. J. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2307–2311. doi: 10.1073/pnas.89.6.2307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bubley G. J., Ashburner B. P., Teicher B. A. Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells. Mol Carcinog. 1991;4(5):397–406. doi: 10.1002/mc.2940040512. [DOI] [PubMed] [Google Scholar]
  9. Calsou P., Frit P., Salles B. Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts. Nucleic Acids Res. 1992 Dec 11;20(23):6363–6368. doi: 10.1093/nar/20.23.6363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chao C. C., Huang S. L., Lee L. Y., Lin-Chao S. Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II). Biochem J. 1991 Aug 1;277(Pt 3):875–878. doi: 10.1042/bj2770875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chow C. S., Whitehead J. P., Lippard S. J. HMG domain proteins induce sharp bends in cisplatin-modified DNA. Biochemistry. 1994 Dec 20;33(50):15124–15130. doi: 10.1021/bi00254a023. [DOI] [PubMed] [Google Scholar]
  12. Chu G., Chang E. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science. 1988 Oct 28;242(4878):564–567. doi: 10.1126/science.3175673. [DOI] [PubMed] [Google Scholar]
  13. Cryer J. E., Johnson S. W., Engelsberg B. N., Billings P. C. Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin. Cancer Chemother Pharmacol. 1996;38(2):163–168. doi: 10.1007/s002800050465. [DOI] [PubMed] [Google Scholar]
  14. Delagoutte E., Bertrand-Burggraf E., Lambert I. B., Fuchs R. P. Binding and incision activities of UvrABC excinuclease on slipped DNA intermediates that generate frameshift mutations. J Mol Biol. 1996 Apr 19;257(5):970–976. doi: 10.1006/jmbi.1996.0216. [DOI] [PubMed] [Google Scholar]
  15. Donahue B. A., Augot M., Bellon S. F., Treiber D. K., Toney J. H., Lippard S. J., Essigmann J. M. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry. 1990 Jun 19;29(24):5872–5880. doi: 10.1021/bi00476a032. [DOI] [PubMed] [Google Scholar]
  16. Drummond J. T., Anthoney A., Brown R., Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem. 1996 Aug 16;271(33):19645–19648. doi: 10.1074/jbc.271.33.19645. [DOI] [PubMed] [Google Scholar]
  17. Duckett D. R., Drummond J. T., Murchie A. I., Reardon J. T., Sancar A., Lilley D. M., Modrich P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6443–6447. doi: 10.1073/pnas.93.13.6443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Eastman A., Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry. 1988 Jun 28;27(13):4730–4734. doi: 10.1021/bi00413a022. [DOI] [PubMed] [Google Scholar]
  19. Fang W. H., Modrich P. Human strand-specific mismatch repair occurs by a bidirectional mechanism similar to that of the bacterial reaction. J Biol Chem. 1993 Jun 5;268(16):11838–11844. [PubMed] [Google Scholar]
  20. Gibbons G. R., Kaufmann W. K., Chaney S. G. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis. 1991 Dec;12(12):2253–2257. doi: 10.1093/carcin/12.12.2253. [DOI] [PubMed] [Google Scholar]
  21. Gunz D., Hess M. T., Naegeli H. Recognition of DNA adducts by human nucleotide excision repair. Evidence for a thermodynamic probing mechanism. J Biol Chem. 1996 Oct 11;271(41):25089–25098. doi: 10.1074/jbc.271.41.25089. [DOI] [PubMed] [Google Scholar]
  22. Hoffmann J. S., Pillaire M. J., Lesca C., Burnouf D., Fuchs R. P., Defais M., Villani G. Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13766–13769. doi: 10.1073/pnas.93.24.13766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Huang J. C., Zamble D. B., Reardon J. T., Lippard S. J., Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10394–10398. doi: 10.1073/pnas.91.22.10394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hughes E. N., Engelsberg B. N., Billings P. C. Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2. J Biol Chem. 1992 Jul 5;267(19):13520–13527. [PubMed] [Google Scholar]
  25. Hwang J. R., Moncollin V., Vermeulen W., Seroz T., van Vuuren H., Hoeijmakers J. H., Egly J. M. A 3' --> 5' XPB helicase defect in repair/transcription factor TFIIH of xeroderma pigmentosum group B affects both DNA repair and transcription. J Biol Chem. 1996 Jul 5;271(27):15898–15904. doi: 10.1074/jbc.271.27.15898. [DOI] [PubMed] [Google Scholar]
  26. Jones C. J., Wood R. D. Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA. Biochemistry. 1993 Nov 16;32(45):12096–12104. doi: 10.1021/bi00096a021. [DOI] [PubMed] [Google Scholar]
  27. Kalnik M. W., Kouchakdjian M., Li B. F., Swann P. F., Patel D. J. Base pair mismatches and carcinogen-modified bases in DNA: an NMR study of G.T and G.O4meT pairing in dodecanucleotide duplexes. Biochemistry. 1988 Jan 12;27(1):108–115. doi: 10.1021/bi00401a018. [DOI] [PubMed] [Google Scholar]
  28. Maher V. M., Dorney D. J., Mendrala A. L., Konze-Thomas B., McCormick J. J. DNA excision-repair processes in human cells can eliminate the cytotoxic and mutagenic consequences of ultraviolet irradiation. Mutat Res. 1979 Sep;62(2):311–323. doi: 10.1016/0027-5107(79)90087-3. [DOI] [PubMed] [Google Scholar]
  29. Mamenta E. L., Poma E. E., Kaufmann W. K., Delmastro D. A., Grady H. L., Chaney S. G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994 Jul 1;54(13):3500–3505. [PubMed] [Google Scholar]
  30. Mello J. A., Acharya S., Fishel R., Essigmann J. M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol. 1996 Jul;3(7):579–589. doi: 10.1016/s1074-5521(96)90149-0. [DOI] [PubMed] [Google Scholar]
  31. Mellon I., Rajpal D. K., Koi M., Boland C. R., Champe G. N. Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science. 1996 Apr 26;272(5261):557–560. doi: 10.1126/science.272.5261.557. [DOI] [PubMed] [Google Scholar]
  32. Moggs J. G., Yarema K. J., Essigmann J. M., Wood R. D. Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J Biol Chem. 1996 Mar 22;271(12):7177–7186. doi: 10.1074/jbc.271.12.7177. [DOI] [PubMed] [Google Scholar]
  33. Mu D., Hsu D. S., Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem. 1996 Apr 5;271(14):8285–8294. doi: 10.1074/jbc.271.14.8285. [DOI] [PubMed] [Google Scholar]
  34. Naser L. J., Pinto A. L., Lippard S. J., Essigmann J. M. Chemical and biological studies of the major DNA adduct of cis-diamminedichloroplatinum(II), cis-[Pt(NH3)2(d(GpG]], built into a specific site in a viral genome. Biochemistry. 1988 Jun 14;27(12):4357–4367. doi: 10.1021/bi00412a024. [DOI] [PubMed] [Google Scholar]
  35. O'Donovan A., Davies A. A., Moggs J. G., West S. C., Wood R. D. XPG endonuclease makes the 3' incision in human DNA nucleotide excision repair. Nature. 1994 Sep 29;371(6496):432–435. doi: 10.1038/371432a0. [DOI] [PubMed] [Google Scholar]
  36. Pil P. M., Lippard S. J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science. 1992 Apr 10;256(5054):234–237. doi: 10.1126/science.1566071. [DOI] [PubMed] [Google Scholar]
  37. Sancar A. DNA excision repair. Annu Rev Biochem. 1996;65:43–81. doi: 10.1146/annurev.bi.65.070196.000355. [DOI] [PubMed] [Google Scholar]
  38. Shivji K. K., Kenny M. K., Wood R. D. Proliferating cell nuclear antigen is required for DNA excision repair. Cell. 1992 Apr 17;69(2):367–374. doi: 10.1016/0092-8674(92)90416-a. [DOI] [PubMed] [Google Scholar]
  39. Sijbers A. M., de Laat W. L., Ariza R. R., Biggerstaff M., Wei Y. F., Moggs J. G., Carter K. C., Shell B. K., Evans E., de Jong M. C. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 1996 Sep 6;86(5):811–822. doi: 10.1016/s0092-8674(00)80155-5. [DOI] [PubMed] [Google Scholar]
  40. Svoboda D. L., Taylor J. S., Hearst J. E., Sancar A. DNA repair by eukaryotic nucleotide excision nuclease. Removal of thymine dimer and psoralen monoadduct by HeLa cell-free extract and of thymine dimer by Xenopus laevis oocytes. J Biol Chem. 1993 Jan 25;268(3):1931–1936. [PubMed] [Google Scholar]
  41. Szymkowski D. E., Hajibagheri M. A., Wood R. D. Electron microscopy of DNA excision repair patches produced by human cell extracts. J Mol Biol. 1993 May 20;231(2):251–260. doi: 10.1006/jmbi.1993.1280. [DOI] [PubMed] [Google Scholar]
  42. Szymkowski D. E., Lawrence C. W., Wood R. D. Repair by human cell extracts of single (6-4) and cyclobutane thymine-thymine photoproducts in DNA. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9823–9827. doi: 10.1073/pnas.90.21.9823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Szymkowski D. E., Yarema K., Essigmann J. M., Lippard S. J., Wood R. D. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10772–10776. doi: 10.1073/pnas.89.22.10772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Takahara P. M., Rosenzweig A. C., Frederick C. A., Lippard S. J. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature. 1995 Oct 19;377(6550):649–652. doi: 10.1038/377649a0. [DOI] [PubMed] [Google Scholar]
  45. Timmer-Bosscha H., Mulder N. H., de Vries E. G. Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer. 1992 Aug;66(2):227–238. doi: 10.1038/bjc.1992.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Toney J. H., Donahue B. A., Kellett P. J., Bruhn S. L., Essigmann J. M., Lippard S. J. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II) Proc Natl Acad Sci U S A. 1989 Nov;86(21):8328–8332. doi: 10.1073/pnas.86.21.8328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Treiber D. K., Zhai X., Jantzen H. M., Essigmann J. M. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5672–5676. doi: 10.1073/pnas.91.12.5672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Visse R., van Gool A. J., Moolenaar G. F., de Ruijter M., van de Putte P. The actual incision determines the efficiency of repair of cisplatin-damaged DNA by the Escherichia coli UvrABC endonuclease. Biochemistry. 1994 Feb 22;33(7):1804–1811. doi: 10.1021/bi00173a025. [DOI] [PubMed] [Google Scholar]
  49. Wood R. D., Burki H. J. Repair capability and the cellular age response for killing and mutation induction after UV. Mutat Res. 1982 Aug;95(2-3):505–514. doi: 10.1016/0027-5107(82)90281-0. [DOI] [PubMed] [Google Scholar]
  50. Wood R. D. DNA repair in eukaryotes. Annu Rev Biochem. 1996;65:135–167. doi: 10.1146/annurev.bi.65.070196.001031. [DOI] [PubMed] [Google Scholar]
  51. Yamada M., O'Regan E., Brown R., Karran P. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res. 1997 Feb 1;25(3):491–496. doi: 10.1093/nar/25.3.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Yang D., van Boom S. S., Reedijk J., van Boom J. H., Wang A. H. Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry. 1995 Oct 3;34(39):12912–12920. doi: 10.1021/bi00039a054. [DOI] [PubMed] [Google Scholar]
  53. Zamble D. B., Lippard S. J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995 Oct;20(10):435–439. doi: 10.1016/s0968-0004(00)89095-7. [DOI] [PubMed] [Google Scholar]
  54. Zamble D. B., Mu D., Reardon J. T., Sancar A., Lippard S. J. Repair of cisplatin--DNA adducts by the mammalian excision nuclease. Biochemistry. 1996 Aug 6;35(31):10004–10013. doi: 10.1021/bi960453+. [DOI] [PubMed] [Google Scholar]
  55. van Garderen C. J., van Houte L. P. The solution structure of a DNA duplex containing the cis-Pt(NH3)2[d(-GTG-)-N7(G),N7(G)] adduct, as determined with high-field NMR and molecular mechanics/dynamics. Eur J Biochem. 1994 Nov 1;225(3):1169–1179. [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES